<i>IKZF1</i> gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia
Britt M. T. Vervoort(Princess Máxima Center), Frank N. van Leeuwen(Princess Máxima Center), Alwin D. R. Huitema(The Netherlands Cancer Institute), Judith M. Boer(Princess Máxima Center), Trisha Tee(Princess Máxima Center), Vincent H. J. van der Velden(Erasmus MC), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Roland P. Kuiper(Princess Máxima Center), Miriam Butler(Cooper Medical School of Rowan University), Dorette S. van Ingen Schenau(Princess Máxima Center), Peter M. Hoogerbrugge(Helios Klinikum Emil von Behring), K Grünewald(Universität Innsbruck), Beat Bornhäuser(University Children's Hospital Zurich), Luc Lucas(The Netherlands Cancer Institute), Laurens T. van der Meer(Princess Máxima Center)
Cited by 4
Related Papers
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1
|Nature Genetics|2008|818
Surviving Stress: Modulation of ATF4-Mediated Stress Responses in Normal and Malignant Cells
|Trends in Endocrinology and Metabolism|2017|635
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451
Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized <i>WT1</i> Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
|Journal of Clinical Oncology|2009|434
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419